Somatrogon: A Literature Course in Six Modules on the Published Evidence

Somatrogon is a long-acting recombinant human growth hormone (rhGH) analogue that has been studied as a once-weekly injection in children with growth hormone deficiency (GHD). A 2022 approval review described somatrogon as a fusion protein combining the human growth hormone sequence with copies of the C-terminal peptide (CTP) of the human chorionic gonadotropin β-subunit, developed to extend the circulating duration of the hormone (PMID 35041176). This page is organised as a six-module reading course through the published literature. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

Each module below summarises what researchers did and what they reported, then closes with the limits of that evidence. No module describes a protocol, and nothing here should be read as a recommendation.

Module 1 — What Somatrogon Is and How It Has Been Studied

Definition and class

Somatrogon belongs to the class of long-acting growth hormone (LAGH) products, a group of engineered rhGH molecules designed for dosing intervals longer than the once-daily schedule used with conventional somatropin. A 2024 expert review discussed somatrogon injection for pediatric growth hormone deficiency alongside other LAGH products and framed them as a distinct therapeutic category within GH replacement (PMID 38112103). A 2025 comprehensive review summarised somatrogon's clinical trial programme and real-world considerations in pediatric GHD (PMID 40049670).

Origin and molecular design

The approval review described the molecule as a CTP-modified growth hormone fusion protein produced by recombinant technology, an approach intended to slow clearance relative to unmodified rhGH (PMID 35041176). That same review noted the product was developed for pediatric GHD and had received its first regulatory approval in that indication (PMID 35041176).

Forms studied

Clinical pharmacology work has examined more than one presentation of the same active substance: a randomised, cross-over study investigated the comparability of somatrogon-ghla delivered in two different drug product presentations (PMID 38923773). The pivotal efficacy studies were conducted as randomised phase 3 trials in children, including a global trial (PMID 35405011) and a separate randomised phase 3 study in Japanese children (PMID 35417909).

Limits of the evidence in Module 1

The descriptive literature is concentrated on pediatric GHD. The verified record here does not establish characterisation in adult GHD, in non-GHD short stature, or in any performance, metabolic or anti-ageing context. Reviews summarise the molecule's design at a high level rather than providing independent structural verification.

Module 2 — Mechanism as Described in the Literature

The mechanism described in published sources is the mechanism of growth hormone itself, delivered with an extended duration of action. The approval review characterised somatrogon as a growth hormone receptor agonist whose CTP modification prolongs its presence in circulation, permitting weekly rather than daily administration (PMID 35041176). The downstream biomarker used across the programme was insulin-like growth factor 1 (IGF-1): a 2025 analysis assessed IGF-1 during weekly somatrogon treatment in pediatric patients with GH deficiency and reported that IGF-1 concentrations varied across the weekly dosing interval, so that the day of sampling influenced how IGF-1 standard deviation scores were interpreted (PMID 39872400).

Comparative reviews placed this mechanism within the broader LAGH class, where different products use different strategies — fusion peptides, albumin binding or pegylation — to extend half-life while retaining growth hormone receptor activity (PMID 38112103). A network meta-analysis of pediatric GHD treatments compared somapacitan with somatrogon and lonapegsomatropin, treating them as pharmacologically distinct long-acting agents evaluated against similar growth endpoints (PMID 39261416).

Limits of the evidence in Module 2

Mechanistic statements in these papers are largely narrative and pharmacological rather than experimental. The verified literature does not provide receptor-binding kinetics, tissue distribution studies or mechanistic animal work. IGF-1 was used as a pharmacodynamic marker, not as proof of any particular downstream pathway.

Module 3 — Reported Outcomes by Study

Global phase 3 trial

The phase 3 study published in 2022 randomised children with growth hormone deficiency to once-weekly somatrogon 0.66 mg/kg/week or once-daily somatropin 0.034 mg/kg/day and used annualised height velocity at 12 months as the primary endpoint, with the researchers reporting that weekly somatrogon met the pre-specified non-inferiority criterion versus daily somatropin (PMID 35405011). A plain-language summary of that publication restated the comparison of weekly somatrogon with daily somatropin in children with growth hormone deficiency and the trial's efficacy and safety conclusions for a non-specialist audience (PMID 39526285).

Japanese phase 3 trial

A separate randomised phase 3 study compared once-weekly somatrogon 0.66 mg/kg/week with once-daily somatropin (Genotropin) 0.034 mg/kg/day in Japanese children with pediatric growth hormone deficiency and reported height velocity and safety results over the randomised treatment period (PMID 35417909).

Indirect comparison

A 2024 systematic literature review and network meta-analysis evaluated the efficacy and safety of somapacitan relative to somatrogon and lonapegsomatropin in pediatric growth hormone deficiency, with the authors reporting the indirect comparisons for growth outcomes and adverse events across the included trials (PMID 39261416).

Transition and real-world reports

A study in Turkish children examined 6-month clinical outcomes and follow-up data in patients transitioned from somatropin to somatrogon, asking whether the weekly product behaved differently in routine care (PMID 42190542). A cross-sectional survey collected physician experience with the once-weekly somatrogon regimen versus a once-daily rhGH regimen among physicians participating in the global phase 3 study (PMID 37955005). A separate health-economic analysis modelled the cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency (PMID 37742226).

Limits of the evidence in Module 3

The pivotal endpoint was height velocity over 12 months, which is a surrogate for growth trajectory rather than adult height. Non-inferiority designs test whether an agent falls within a pre-specified margin of a comparator; they do not demonstrate superiority. The network meta-analysis relied on indirect comparison across trials with differing populations and methods (PMID 39261416), and the economic model reflected assumptions specific to one health system (PMID 37742226). Survey and transition data are observational and unblinded.

Module 4 — Somatrogon Side Effects: What Studies Report

Adverse events in the somatrogon literature were reported mainly from the randomised phase 3 programme and from reviews summarising it. In the global phase 3 study, researchers reported that the overall frequency of treatment-emergent adverse events was broadly similar between the weekly somatrogon and daily somatropin arms, while injection-site reactions — injection-site pain in particular — were reported more frequently in the somatrogon group (PMID 35405011). The Japanese phase 3 study also reported injection-site reactions among the adverse events observed with once-weekly somatrogon compared with once-daily somatropin (PMID 35417909).

The plain-language summary of the global trial described the safety findings in accessible terms, including that injection-site pain was among the events reported more often with the weekly injection (PMID 39526285). The 2024 network meta-analysis assessed safety alongside efficacy when comparing long-acting growth hormone products in pediatric GHD and reported the adverse-event comparisons available from the included trials (PMID 39261416). Narrative reviews of somatrogon and other LAGH products likewise discussed tolerability and injection-site findings as part of the product profile (PMID 38112103), and the 2025 comprehensive review revisited trial safety data together with real-world considerations (PMID 40049670).

Because IGF-1 exposure is monitored during growth hormone therapy, the 2025 IGF-1 analysis is relevant to safety interpretation: it reported that IGF-1 levels changed across the weekly interval, meaning that a single measurement could over- or under-represent average exposure depending on sampling day (PMID 39872400).

Limits of the evidence in Module 4

Published adverse-event data derive largely from 12-month randomised comparisons in children with GHD, so rare events, delayed events and outcomes beyond the trial horizon were not captured. Safety reporting in non-GHD populations, in adults and in unsupervised use is absent from the verified record. Injection-site findings were reported in the context of a weekly versus daily injection schedule, which differ in injection number and volume, and the literature does not resolve every contributor to those differences.

Module 5 — Pharmacokinetics Where Data Exist

The pharmacokinetic rationale stated in the approval review was that CTP fusion extends the circulating duration of growth hormone sufficiently to support once-weekly rather than once-daily dosing (PMID 35041176). Formal clinical pharmacology work included a randomised, cross-over study that investigated whether somatrogon-ghla administered from two different drug product presentations produced comparable exposure, with the authors reporting the comparability assessment between presentations (PMID 38923773).

On the pharmacodynamic side, the IGF-1 assessment study characterised the time course of IGF-1 during weekly somatrogon treatment in pediatric patients and reported that the measured IGF-1 standard deviation score depended on where in the weekly interval the sample was drawn (PMID 39872400). Reviews of the LAGH class discussed how differing half-life extension strategies translate into different exposure profiles across products (PMID 38112103).

Limits of the evidence in Module 5

The verified record does not supply specific half-life values, clearance estimates, bioavailability percentages or volume-of-distribution figures for somatrogon. Comparability work addressed presentation-to-presentation equivalence rather than absolute pharmacokinetic parameters, and IGF-1 kinetics are a downstream marker rather than direct drug measurement. No pharmacokinetic data in adults, in renal or hepatic impairment, or with alternative routes appear in these sources.

Module 6 — Regulatory Status, Stated Factually

Somatrogon is a regulated biologic rather than a research chemical. The 2022 Drugs approval article reported its first regulatory approval for the treatment of pediatric growth hormone deficiency and described the product's development by its sponsors (PMID 35041176). Subsequent reviews discussed somatrogon as an available long-acting growth hormone option for pediatric GHD within clinical practice (PMID 40049670) and compared it with other approved LAGH products (PMID 38112103). Health-system assessment has also occurred: a cost-effectiveness analysis evaluated somatrogon in the Spanish pediatric population with growth hormone deficiency (PMID 37742226), the kind of appraisal typically undertaken after marketing authorisation.

Research-use-only material and compounding

Materials labelled "research use only" (RUO) are supplied for laboratory work and are not authorised for administration to humans; RUO labelling carries no assurance of identity, sterility or purity suitable for clinical use. Somatrogon is a recombinant fusion protein regulated as a biologic, and biologic products sit outside the pathways used for traditional small-molecule or peptide compounding in many jurisdictions; approvals and permitted uses are defined by each national regulator. Regulatory frameworks differ by country and change over time, and this section is descriptive only. Nothing on this page is legal advice.

Limits of the evidence in Module 6

The verified literature records approval in the pediatric GHD indication and subsequent clinical and economic appraisal, but it is not a current register of every jurisdiction, label change, age restriction or reimbursement decision. Regulatory status should be confirmed against primary regulator documents rather than review articles.

What the Studies Did Not Test

Reading the verified set together, several questions remain outside the published evidence base:

• Adult use. The trials summarised here enrolled children with growth hormone deficiency (PMID 35405011) (PMID 35417909); adult GHD outcomes were not the subject of these reports.
• Final adult height. The pivotal endpoint was annualised height velocity at 12 months rather than attained adult height (PMID 35405011).
• Non-deficient populations. No verified study evaluated somatrogon in people without growth hormone deficiency, including for body composition, athletic performance or ageing.
• Long-term safety. Randomised safety comparisons covered 12 months (PMID 35405011), with shorter observational follow-up in a transition cohort (PMID 42190542); multi-year and lifetime outcomes were not established.
• Head-to-head LAGH trials. Comparisons between long-acting products in the verified set were indirect (PMID 39261416) rather than direct randomised comparisons.
• Combination use. No verified study examined somatrogon combined with other peptides or hormones.

Readers interested in how physicians described the practical differences between regimens can note that a cross-sectional survey of phase 3 investigators collected experience with the once-weekly versus once-daily approach (PMID 37955005); that survey measured perceptions, not clinical outcomes. As with every module above, the material here summarises what the studies reported and is not guidance for use. This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on any health information.

References

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Somatrogon: First Approval (Drugs, 2022)
• Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis (Advances in Therapy, 2024)
• Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study (Hormone Research in Paediatrics, 2022)
• Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products (Expert Review of Endocrinology & Metabolism, 2024)
• Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency (Expert Review of Pharmacoeconomics & Outcomes Research, 2023)
• A Randomized, Cross-Over Study Investigating the Comparability of Somatrogon-ghla in 2 Different Drug Product Presentations (Clinical Pharmacology in Drug Development, 2024)
• Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations (Annals of Pediatric Endocrinology & Metabolism, 2025)
• Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication (Therapeutic Advances in Endocrinology and Metabolism, 2024)
• Is Somatrogon different? 6-month clinical outcomes and follow-up data in Turkish children transitioned from Somatropin to Somatrogon (Growth Hormone & IGF Research, 2026)
• IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency (Journal of the Endocrine Society, 2025)
• Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study (Frontiers in Endocrinology, 2023)